医学
前列腺癌
活检
放射科
磁共振成像
近距离放射治疗
前列腺
谷氨酸羧肽酶Ⅱ
放射治疗
超声波
正电子发射断层摄影术
癌症
核医学
内科学
作者
M. Rasing,Marieke van Son,Marinus A. Moerland,Bart de Keizer,Frank J. Wessels,Trudy Jonges,S. van de Pol,Wietse S.C. Eppinga,Juus L Noteboom,J J W Lagendijk,Jochem van der Voort van Zijp,Max Peters
出处
期刊:Cancers
[Multidisciplinary Digital Publishing Institute]
日期:2022-02-03
卷期号:14 (3): 781-781
被引量:15
标识
DOI:10.3390/cancers14030781
摘要
Radiorecurrent prostate cancer is conventionally confirmed using systematic and/or targeted biopsies. The availability of multiparametric (mp) MRI and prostate specific membrane antigen (PSMA) PET/CT has increased diagnostic accuracy. The objective was to determine the positive predictive value (PPV) of combined mp-MRI and PSMA PET/CT and whether pathology verification with MR-targeted biopsies remains necessary for patients with radiorecurrent prostate cancer. Patients with locally recurrent prostate cancer who were referred for 19 Gy single-dose MRI-guided focal salvage high dose rate (HDR) brachytherapy between 2015 and 2018 were included in the current analysis. Patients were selected if they underwent pre-biopsy mp-MRI and PSMA PET/CT. Based on these images, lesions suspect for isolated tumor recurrence were transperineally biopsied using transrectal ultrasound fused with MRI. A total of 41 patients were identified from the database who underwent cognitive targeted (n = 7) or MRI/PSMA-transrectal ultrasound (TRUS) fused targeted (n = 34) biopsies. A total of 40 (97.6%) patients had positive biopsies for recurrent cancer. Five patients initially had negative biopsies (all MRI/PSMA-TRUS fusion targeted), four of whom recurrence was confirmed after a re-biopsy. One (2.4%) patient refused re-biopsy, leading to a positive predictive value (PPV) for combined imaging of 97.6%. Biopsies can therefore safely be withheld when the results of the combined mp-MRI and PSMA PET/CT are conclusive, avoiding an unnecessary invasive and burdensome procedure.
科研通智能强力驱动
Strongly Powered by AbleSci AI